Brainstorm Cell Therapeutics EBIT

The latest EBIT for BCLI is $5.7M as of June 2026. That compares with $-12M in the prior-year period — up 147.6% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Brainstorm Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BCLI's EBIT moved from $-12M to $5.7M — a 147.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brainstorm Cell Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, BCLI currently prints $5.7M for EBIT, while the sector average sits near $23B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Brainstorm Cell Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $5.7M for BCLI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting BCLI's EBIT ($5.7M), review year-over-year change from $-12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.